Increased expression of thymidylate synthetase (TS), ubiquitin specific protease 10 (USP10) and survivin is associated with poor survival in glioblastoma multiforme (GBM)

Jessica M. Grunda, L. Burton Nabors, Cheryl A. Palmer, David C. Chhieng, Adam Steg, Tom Mikkelsen, Robert B. Diasio, Kui Zhang, David Allison, William E. Grizzle, Wenquan Wang, G. Yancey Gillespie, Martin R. Johnson

Research output: Contribution to journalArticle

28 Scopus citations

Abstract

Background: The limited success of empirically designed treatment paradigms for patients diagnosed with glioblastoma multiforme (GBM) emphasizes the need for rationally designed treatment strategies based on the molecular profile of tumor samples and their correlation to clinical parameters. Methods: In the current study, we utilize a novel real-time quantitative low density array (RTQ-LDA) to identify differentially expressed genes in de novo GBM tissues obtained from patients with distinctly different clinical outcomes. Total RNA was isolated from a cohort of 21 GBM specimens obtained from patients with either good (long-term survival (LTS) >36 months post surgery, n = 8) or poor (died of the disease (DOD) <24 months post surgery, n = 13) prognosis. Non-neoplastic brain tissue (n = 5) was obtained from patients who underwent surgery for refractory epilepsy. Demographic data was assessed for correlation with survival using Cox proportional hazards models. Sufficient RNA was available to use RTQ-LDA to quantify the expression of 93 independent genes in 5 LTS, 4 DOD, and 5 non-neoplastic brain samples. The eight differentially expressed genes identified by RTQ-LDA in LTS versus DOD (P ≤ 0.050) were subsequently quantified in all 21 GBM samples by real-time quantitative PCR (RTQ). Results: A correlation between younger patients and good prognosis was demonstrated (P ≤ 0.05). The combination of RTQ-LDA and RTQ identified thymidylate synthetase (TS), ubiquitin specific protease 10 (USP10), and survivin as significantly over-expressed (P ≤ 0.050) in DOD compared to LTS patients. Ribonucleotide reductase subunit M2 (RRM2) was identified as tumor-specific, but not associated with survival. Conclusions: Taken collectively, TS, USP10, survivin and RRM2 may be useful as prognostic indicators and/or in the development of rationally designed treatment protocols.

Original languageEnglish (US)
Pages (from-to)261-274
Number of pages14
JournalJournal of neuro-oncology
Volume80
Issue number3
DOIs
StatePublished - Dec 1 2006

Keywords

  • Glioblastoma multiforme
  • Glioma
  • Low density array
  • Real-time quantitative PCR
  • Ribonucleotide reductase subunit M2
  • Survival
  • Survivin
  • Thymidylate synthetase
  • Ubiquitin specific protease 10

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Fingerprint Dive into the research topics of 'Increased expression of thymidylate synthetase (TS), ubiquitin specific protease 10 (USP10) and survivin is associated with poor survival in glioblastoma multiforme (GBM)'. Together they form a unique fingerprint.

  • Cite this

    Grunda, J. M., Nabors, L. B., Palmer, C. A., Chhieng, D. C., Steg, A., Mikkelsen, T., Diasio, R. B., Zhang, K., Allison, D., Grizzle, W. E., Wang, W., Gillespie, G. Y., & Johnson, M. R. (2006). Increased expression of thymidylate synthetase (TS), ubiquitin specific protease 10 (USP10) and survivin is associated with poor survival in glioblastoma multiforme (GBM). Journal of neuro-oncology, 80(3), 261-274. https://doi.org/10.1007/s11060-006-9191-4